143 related articles for article (PubMed ID: 10373776)
1. [Expression of inducible nitric oxide synthase in the carotid of rats after endothelial skinning: the effects of platelets and treatment with abciximab].
González-Fernández F; Rodríguez-Feo JA; Farré J; Guerra J; Romero J; Gómez J; Rico L; Ayala R; Marcos P; Sánchez de Miguel L; Casado S; López-Farré A
Rev Esp Cardiol; 1999 Jun; 52(6):422-8. PubMed ID: 10373776
[TBL] [Abstract][Full Text] [Related]
2. Expression of inducible nitric oxide synthase after endothelial denudation of the rat carotid artery: role of platelets.
González-Fernández F; López-Farré A; Rodríguez-Feo JA; Farré J; Guerra J; Fortes J; Millás I; García-Durán M; Rico L; Mata P; de Miguel LS; Casado S
Circ Res; 1998 Nov; 83(11):1080-7. PubMed ID: 9831702
[TBL] [Abstract][Full Text] [Related]
3. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
Tam SH; Sassoli PM; Jordan RE; Nakada MT
Circulation; 1998 Sep; 98(11):1085-91. PubMed ID: 9736595
[TBL] [Abstract][Full Text] [Related]
4. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
Straub A; Wendel HP; Azevedo R; Ziemer G
Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty.
Wu CH; Chen YC; Hsiao G; Lin CH; Liu CM; Sheu JR
Thromb Res; 2001 Feb; 101(3):127-38. PubMed ID: 11228336
[TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa receptor antagonist (abciximab) inhibited platelet activation and promoted skin flap survival after ischemia/reperfusion injury.
Kuo YR; Jeng SF; Wang FS; Huang HC; Wei FC; Yang KD
J Surg Res; 2002 Sep; 107(1):50-5. PubMed ID: 12384064
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
8. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
[TBL] [Abstract][Full Text] [Related]
9. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery.
Yan ZQ; Yokota T; Zhang W; Hansson GK
Circ Res; 1996 Jul; 79(1):38-44. PubMed ID: 8925566
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein IIB/IIIA-inhibition and microcirculatory alterations during experimental endotoxemia--an intravital microscopic study in the rat.
Walther A; Czabanka M; Gebhard MM; Martin E
Microcirculation; 2004; 11(1):79-88. PubMed ID: 15280099
[TBL] [Abstract][Full Text] [Related]
11. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
12. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
16. Effects of endothelium/leukocytes/platelet interaction on myocardial ischemia--reperfusion injury.
Habazettl H; Hanusch P; Kupatt C
Z Kardiol; 2000; 89 Suppl 9():IX/92-5. PubMed ID: 11151804
[TBL] [Abstract][Full Text] [Related]
17. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
Mascelli MA; Lance ET; Damaraju L; Wagner CL; Weisman HF; Jordan RE
Circulation; 1998 May; 97(17):1680-8. PubMed ID: 9591761
[TBL] [Abstract][Full Text] [Related]
19. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
[TBL] [Abstract][Full Text] [Related]
20. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
